StockCIK 1841387

Candel Therapeutics, Inc. (CADL): Insider Trades and Fund Holdings

In the past 12 months, Candel Therapeutics, Inc. insiders reported 0 open-market purchases worth $0 and 3 sales worth $3.24M; 3 of the sales were reported as made under a 10b5-1 trading plan.

0Insider buys, 12 months

$0Bought by insiders, 12 months

$3.24MSold by insiders, 12 months

0Tracked funds holding

Recent insider trades

Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Sep 11, 2026.

Recent CADL insider trades
Filed	Traded	Insider	Role	Type	Shares	Price ($)	Value	Holding	Filing
Sep 11	Sep 10	Paul Peter TakCEO	CEO	▼ SELL10b5-1	220,866	11.50	$2.54M	−56%	Form 4 ↗
Sep 11	Sep 11	Paul Peter TakCEO	CEO	▼ SELL10b5-1	59,379	10.46	$621K	−34%	Form 4 ↗
Aug 19	Aug 17	Seshu TyagarajanCTO	CTO	▼ SELL10b5-1	7,000	12.00	$84K	−8.3%	Form 4 ↗

Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings

Insiders who traded in the past year

Insider	Role	Buys	Bought	Sells	Sold	Latest
Paul Peter Tak	CEO	0	$0	2	$3.16M	Sep 11, 2026
Seshu Tyagarajan	CTO	0	$0	1	$84K	Aug 19, 2026

Tracked funds that report CADL

From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.

Fund	Quarter	Shares	Value	% of portfolio	Change
Renaissance Technologies	Q2 2026	0	$0	0.00%	▼ Sold out

Source: SEC Form 13F-HR filings, retrieved Oct 28, 2026. How we read filings

Reading these numbers

Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →